Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Cancer and Metastasis Reviews
Erschienen in: Cancer and Metastasis Reviews 1-2/2013

01.06.2013

Mouse models of BRCA1 and their application to breast cancer research

verfasst von: Jennifer Dine, Chu-Xia Deng

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 1-2/2013

Einloggen, um Zugang zu erhalten

Abstract

Germline mutations of human breast cancer-associated gene 1 (BRCA1) predispose women to breast and ovarian cancers. In mice, over 20 distinct mutations, including null, hypomorphic, isoform, conditional, and point mutations, have been created to study functions of Brca1 in mammary development and tumorigenesis. Analyses using these mutant mice have yielded an enormous amount of information that greatly facilitates our understanding of the gender- and tissue-specific tumor suppressor functions of BRCA1, as well as enriches our insights into applying these preclinical models of disease to breast cancer research. Here, we review features of these mutant mice and their applications to cancer prevention and therapeutic treatment.
Literatur
1.
DeSantis, C., Siegel, R., Bandi, P., & Jemal, A. (2011). Breast cancer statistics, 2011. CA: a Cancer Journal for Clinicians, 61, 409–418.CrossRef
2.
Hall, J. M., Lee, M. K., Newman, B., Morrow, J. E., Anderson, L. A., Huey, B., & King, M. C. (1990). Linkage of early-onset familial breast cancer to chromosome 17q21. Science, 250, 1684–1689.PubMedCrossRef
3.
Miki, Y., Swensen, J., Shattuck-Eidens, D., Futreal, P. A., Harshman, K., Tavtigian, S., Liu, Q., Cochran, C., Bennett, L. M., Ding, W., et al. (1994). A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science, 266, 66–71.PubMedCrossRef
4.
Alberg, A. J., & Helzlsouer, K. J. (1997). Epidemiology, prevention, and early detection of breast cancer. Current Opinion in Oncology, 9, 505–511.PubMedCrossRef
5.
Brody, L. C., & Biesecker, B. B. (1998). Breast cancer susceptibility genes. BRCA1 and BRCA2. Medicine (Baltimore), 77, 208–226.CrossRef
6.
Eccles, D. M., & Pichert, G. (2005). Familial non-BRCA1/BRCA2-associated breast cancer. The Lancet Oncology, 6, 705–711.PubMedCrossRef
7.
Zhang, J., & Powell, S. N. (2005). The role of the BRCA1 tumor suppressor in DNA double-strand break repair. Molecular Cancer Research, 3, 531–539.PubMedCrossRef
8.
Lane, T. F., Deng, C., Elson, A., Lyu, M. S., Kozak, C. A., & Leder, P. (1995). Expression of Brca1 is associated with terminal differentiation of ectodermally and mesodermally derived tissues in mice. Genes & Development, 9, 2712–2722.CrossRef
9.
ElShamy, W. M., & Livingston, D. M. (2004). Identification of BRCA1-IRIS, a BRCA1 locus product. Nature Cell Biology, 6, 954–967. Epub 2004 Sep 2026.PubMedCrossRef
10.
Thakur, S., Zhang, H. B., Peng, Y., Le, H., Carroll, B., Ward, T., Yao, J., Farid, L. M., Couch, F. J., Wilson, R. B., & Weber, B. L. (1997). Localization of BRCA1 and a splice variant identifies the nuclear localization signal. Molecular and Cellular Biology, 17, 444–452.PubMed
11.
Wilson, C. A., Payton, M. N., Elliott, G. S., Buaas, F. W., Cajulis, E. E., Grosshans, D., Ramos, L., Reese, D. M., Slamon, D. J., & Calzone, F. J. (1997). Differential subcellular localization, expression and biological toxicity of BRCA1 and the splice variant BRCA1-delta11b. Oncogene, 14, 1–16.PubMedCrossRef
12.
Xu, X., Weaver, Z., Linke, S. P., Li, C., Gotay, J., Wang, X. W., Harris, C. C., Ried, T., & Deng, C. X. (1999). Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells. Molecular Cell, 3, 389–395.PubMedCrossRef
13.
Paterson, J. W. (1998). BRCA1: a review of structure and putative functions. Disease Markers, 13, 261–274.PubMed
14.
Deng, C. X. (2006). BRCA1: cell cycle checkpoint, genetic instability, DNA damage response, and cancer evolution. Nucleic Acids Research, 34, 1416–1426.PubMedCrossRef
15.
Deng, C. X., & Brodie, S. G. (2000). Roles of BRCA1 and its interacting proteins. Bioessays, 22, 728–737.PubMedCrossRef
16.
Deng, C. X. (2002). Tumor formation in Brca1 conditional mutant mice. Environmental and Molecular Mutagenesis, 39, 171–177.PubMedCrossRef
17.
Deng, C. X., & Wang, R. H. (2003). Roles of BRCA1 in DNA damage repair: a link between development and cancer. Human Molecular Genetics, 12, R113–R123.PubMedCrossRef
18.
Diaz-Cruz, E. S., Cabrera, M. C., Nakles, R., Rutstein, B. H., & Furth, P. A. (2010). BRCA1 deficient mouse models to study pathogenesis and therapy of triple negative breast cancer. Breast Disease, 32, 85–97.PubMed
19.
Drost, R. M., & Jonkers, J. (2009). Preclinical mouse models for BRCA1-associated breast cancer. British Journal of Cancer, 101, 1651–1657.PubMedCrossRef
20.
Hu, Y. (2009). BRCA1, hormone, and tissue-specific tumor suppression. International Journal of Biological Sciences, 5, 20–27.PubMedCrossRef
21.
Roy, R., Chun, J., & Powell, S. N. (2012). BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nature Reviews. Cancer, 12, 68–78.CrossRef
22.
Venkitaraman, A. R. (2002). Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell, 108, 171–182.PubMedCrossRef
23.
Capecchi, M. R. (1989). Altering the genome by homologous recombination. Science, 244, 1288–1292 [Review].PubMedCrossRef
24.
Xu, X., Li, C., Garrett-Beal, L., Larson, D., Wynshaw-Boris, A., & Deng, C. X. (2001). Direct removal in the mouse of a floxed neo gene from a three-loxP conditional knockout allele by two novel approaches. Genesis, 30, 1–6.PubMedCrossRef
25.
Hakem, R., de la Pompa, J. L., Elia, A., Potter, J., & Mak, T. W. (1997). Partial rescue of Brca1 (5–6) early embryonic lethality by p53 or p21 null mutation. Nature Genetics, 16, 298–302.PubMedCrossRef
26.
Ludwig, T., Chapman, D. L., Papaioannou, V. E., & Efstratiadis, A. (1997). Targeted mutations of breast cancer susceptibility gene homologs in mice: lethal phenotypes of Brca1, Brca2, Brca1/Brca2, Brca1/p53, and Brca2/p53 nullizygous embryos. Genes & Development, 11, 1226–1241.CrossRef
27.
Shen, S. X., Weaver, Z., Xu, X., Li, C., Weinstein, M., Chen, L., Guan, X. Y., Ried, T., & Deng, C. X. (1998). A targeted disruption of the murine Brca1 gene causes gamma-irradiation hypersensitivity and genetic instability. Oncogene, 17, 3115–3124.PubMedCrossRef
28.
Ludwig, T., Fisher, P., Ganesan, S., & Efstratiadis, A. (2001). Tumorigenesis in mice carrying a truncating Brca1 mutation. Genes & Development, 15, 1188–1193.CrossRef
29.
Kim, S. S., Cao, L., Lim, S. C., Li, C., Wang, R. H., Xu, X., Bachelier, R., & Deng, C. X. (2006). Hyperplasia and spontaneous tumor development in the gynecologic system in mice lacking the BRCA1-Delta11 isoform. Molecular and Cellular Biology, 26, 6983–6992.PubMedCrossRef
30.
Xu, X., Qiao, W., Linke, S. P., Cao, L., Li, W. M., Furth, P. A., Harris, C. C., & Deng, C. X. (2001). Genetic interactions between tumor suppressors Brca1 and p53 in apoptosis, cell cycle and tumorigenesis. Nature Genetics, 28, 266–271.PubMedCrossRef
31.
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Jr., Butel, J. S., & Bradley, A. (1992). Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature, 356, 215–221.PubMedCrossRef
32.
Bachelier, R., Xu, X., Wang, X., Li, W., Naramura, M., Gu, H., & Deng, C. X. (2003). Normal lymphocyte development and thymic lymphoma formation in Brca1 exon 11-deficient mice. Oncogene, 22, 528–537.PubMedCrossRef
33.
Cao, L., Li, W., Kim, S., Brodie, S. G., & Deng, C. X. (2003). Senescence, aging, and malignant transformation mediated by p53 in mice lacking the Brca1 full-length isoform. Genes & Development, 17, 201–213.CrossRef
34.
Cao, L., Xu, X., Cao, L. L., Wang, R. H., Coumoul, X., Kim, S. S., & Deng, C. X. (2007). Absence of full-length Brca1 sensitizes mice to oxidative stress and carcinogen-induced tumorigenesis in the esophagus and forestomach. Carcinogenesis, 28, 1401–1407.PubMedCrossRef
35.
Crook, T., Brooks, L. A., Crossland, S., Osin, P., Barker, K. T., Waller, J., Philp, E., Smith, P. D., Yulug, I., Peto, J., Parker, G., Allday, M. J., Crompton, M. R., & Gusterson, B. A. (1998). p53 mutation with frequent novel condons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumours. Oncogene, 17, 1681–1689.PubMedCrossRef
36.
Crook, T., Crossland, S., Crompton, M. R., Osin, P., & Gusterson, B. A. (1997). p53 mutations in BRCA1-associated familial breast cancer. Lancet, 350, 638–639.PubMedCrossRef
37.
Bunting, S. F., Callen, E., Wong, N., Chen, H. T., Polato, F., Gunn, A., Bothmer, A., Feldhahn, N., Fernandez-Capetillo, O., Cao, L., Xu, X., Deng, C. X., Finkel, T., Nussenzweig, M., Stark, J. M., & Nussenzweig, A. (2010). 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. Cell, 141, 243–254.PubMedCrossRef
38.
Cao, L., Kim, S., Xiao, C., Wang, R. H., Coumoul, X., Wang, X., Li, W., Xu, X., De Soto, J., Takai, H., Mai, S., Elledge, S. J., Motoyama, N., & Deng, C. (2006). ATM-Chk2-p53 activation prevents tumorigenesis at an expense of organ homeostasis upon Brca1 deficiency. EMBO Journal, 25, 2167–2177.PubMedCrossRef
39.
Cao, L., Xu, X., Bunting, S. F., Liu, J., Wang, R. H., Cao, L. L., Wu, J. J., Peng, T. N., Chen, J., Nussenzweig, A., Deng, C. X., & Finkel, T. (2009). A selective requirement for 53BP1 in the biological response to genomic instability induced by Brca1 deficiency. Molecular Cell, 35, 534–541.PubMedCrossRef
40.
Bunting, S. F., Callen, E., Kozak, M. L., Kim, J. M., Wong, N., Lopez-Contreras, A. J., Ludwig, T., Baer, R., Faryabi, R. B., Malhowski, A., Chen, H. T., Fernandez-Capetillo, O., D’Andrea, A., & Nussenzweig, A. (2012). BRCA1 functions independently of homologous recombination in DNA interstrand crosslink repair. Molecular Cell, 46(2), 125–135.PubMedCrossRef
41.
Xu, X., Wagner, K. U., Larson, D., Weaver, Z., Li, C., Ried, T., Hennighausen, L., Wynshaw-Boris, A., & Deng, C. X. (1999). Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation. Nature Genetics, 22, 37–43 [see comments].PubMedCrossRef
42.
Wagner, K. U., Wall, R. J., St-Onge, L., Gruss, P., Wynshaw-Boris, A., Garrett, L., Li, M., Furth, P. A., & Hennighausen, L. (1997). Cre-mediated gene deletion in the mammary gland. Nucleic Acids Research, 25, 4323–4330.PubMedCrossRef
43.
Weaver, Z., Montagna, C., Xu, X., Howard, T., Gadina, M., Brodie, S. G., Deng, C. X., & Ried, T. (2002). Mammary tumors in mice conditionally mutant for Brca1 exhibit gross genomic instability and centrosome amplification yet display a recurring distribution of genomic imbalances that is similar to human breast cancer. Oncogene, 21, 5097–5107.PubMedCrossRef
44.
Wang, R. H., Yu, H., & Deng, C. X. (2004). A requirement for breast-cancer-associated gene 1 (BRCA1) in the spindle checkpoint. Proceedings of the National Academy of Sciences of the United States of America, 101, 17108–17113.PubMedCrossRef
45.
Nanda, R. (2011). “Targeting” triple-negative breast cancer: the lessons learned from BRCA1-associated breast cancers. Seminars in Oncology, 38, 254–262.PubMedCrossRef
46.
Rastelli, F., Biancanelli, S., Falzetta, A., Martignetti, A., Casi, C., Bascioni, R., Giustini, L., & Crispino, S. (2010). Triple-negative breast cancer: current state of the art. Tumori, 96, 875–888.PubMed
47.
Cortez, D., Wang, Y., Qin, J., & Elledge, S. J. (1999). Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks. Science, 286, 1162–1166.PubMedCrossRef
48.
Lou, Z., Chini, C. C., Minter-Dykhouse, K., & Chen, J. (2003). Mediator of DNA damage checkpoint protein 1 regulates BRCA1 localization and phosphorylation in DNA damage checkpoint control. Journal of Biological Chemistry, 278, 13599–13602.PubMedCrossRef
49.
Zhou, B. B., & Elledge, S. J. (2000). The DNA damage response: putting checkpoints in perspective. Nature, 408, 433–439.PubMedCrossRef
50.
Kim, S. S., Cao, L., Baek, H. J., Lim, S. C., Li, C., Wang, R. H., Xu, X., Cho, K. H., & Deng, C. X. (2009). Impaired skin and mammary gland development and increased gamma-irradiation-induced tumorigenesis in mice carrying a mutation of S1152-ATM phosphorylation site in Brca1. Cancer Research, 69, 9291–9300.PubMedCrossRef
51.
Kim, S. S., Cao, L., Li, C., Xu, X., Huber, L. J., Chodosh, L. A., & Deng, C. X. (2004). Uterus hyperplasia and increased carcinogen-induced tumorigenesis in mice carrying a targeted mutation of the Chk2 phosphorylation site in Brca1. Molecular and Cellular Biology, 24, 9498–9507.PubMedCrossRef
52.
Chang, S., Biswas, K., Martin, B. K., Stauffer, S., & Sharan, S. K. (2009). Expression of human BRCA1 variants in mouse ES cells allows functional analysis of BRCA1 mutations. The Journal of Clinical Investigation, 119, 3160–3171.PubMedCrossRef
53.
54.
Turner, J. M., Aprelikova, O., Xu, X., Wang, R., Kim, S., Chandramouli, G. V., Barrett, J. C., Burgoyne, P. S., & Deng, C. X. (2004). BRCA1, histone H2AX phosphorylation, and male meiotic sex chromosome inactivation. Current Biology, 14, 2135–2142.PubMedCrossRef
55.
Xu, X., Aprelikova, O., Moens, P., Deng, C. X., & Furth, P. A. (2003). Impaired meiotic DNA-damage repair and lack of crossing-over during spermatogenesis in BRCA1 full-length isoform deficient mice. Development, 130, 2001–2012.PubMedCrossRef
56.
Monteiro, A. N. (2003). BRCA1: the enigma of tissue-specific tumor development. Trends in Genetics, 19, 312–315.PubMedCrossRef
57.
Elledge, S. J., & Amon, A. (2002). The BRCA1 suppressor hypothesis: an explanation for the tissue-specific tumor development in BRCA1 patients. Cancer Cell, 1, 129–132.PubMedCrossRef
58.
Trauernicht, A. M., & Boyer, T. G. (2003). BRCA1 and estrogen signaling in breast cancer. Breast Disease, 18, 11–20.PubMed
59.
Calderon-Margalit, R., & Paltiel, O. (2004). Prevention of breast cancer in women who carry BRCA1 or BRCA2 mutations: a critical review of the literature. International Journal of Cancer, 112, 357–364.CrossRef
60.
Gadducci, A., Biglia, N., Sismondi, P., & Genazzani, A. R. (2005). Breast cancer and sex steroids: critical review of epidemiological, experimental and clinical investigations on etiopathogenesis, chemoprevention and endocrine treatment of breast cancer. Gynecological Endocrinology, 20, 343–360.PubMedCrossRef
61.
Prall, O. W., Rogan, E. M., & Sutherland, R. L. (1998). Estrogen regulation of cell cycle progression in breast cancer cells. The Journal of Steroid Biochemistry and Molecular Biology, 65, 169–174.PubMedCrossRef
62.
Fan, S., Wang, J., Yuan, R., Ma, Y., Meng, Q., Erdos, M. R., Pestell, R. G., Yuan, F., Auborn, K. J., Goldberg, I. D., & Rosen, E. M. (1999). BRCA1 inhibition of estrogen receptor signaling in transfected cells. Science, 284, 1354–1356.PubMedCrossRef
63.
Zheng, L., Annab, L. A., Afshari, C. A., Lee, W. H., & Boyer, T. G. (2001). BRCA1 mediates ligand-independent transcriptional repression of the estrogen receptor. Proceedings of the National Academy of Sciences of the United States of America, 98, 9587–9592.PubMedCrossRef
64.
Hu, Y., Ghosh, S., Amleh, A., Yue, W., Lu, Y., Katz, A., & Li, R. (2005). Modulation of aromatase expression by BRCA1: a possible link to tissue-specific tumor suppression. Oncogene, 24, 8343–8348.PubMedCrossRef
65.
Jones, L. P., Tilli, M. T., Assefnia, S., Torre, K., Halama, E. D., Parrish, A., Rosen, E. M., & Furth, P. A. (2008). Activation of estrogen signaling pathways collaborates with loss of Brca1 to promote development of ERalpha-negative and ERalpha-positive mammary preneoplasia and cancer. Oncogene, 27, 794–802.PubMedCrossRef
66.
Li, W., Xiao, C., Vonderhaar, B. K., & Deng, C. X. (2007). A role of estrogen/ERalpha signaling in BRCA1-associated tissue-specific tumor formation. Oncogene, 26, 7204–7212.PubMedCrossRef
67.
Eisinger, F., Jacquemier, J., Nogues, C., Birnbaum, D., & Sobol, H. (1999). Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes. Cancer, 85, 2291–2295.PubMedCrossRef
68.
Johannsson, O. T., Idvall, I., Anderson, C., Borg, A., Barkardottir, R. B., Egilsson, V., & Olsson, H. (1997). Tumour biological features of BRCA1-induced breast and ovarian cancer. European Journal of Cancer, 33, 362–371.PubMedCrossRef
69.
Karp, S. E., Tonin, P. N., Begin, L. R., Martinez, J. J., Zhang, J. C., Pollak, M. N., & Foulkes, W. D. (1997). Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women. Cancer, 80, 435–441.PubMedCrossRef
70.
Foulkes, W. D., Metcalfe, K., Sun, P., Hanna, W. M., Lynch, H. T., Ghadirian, P., Tung, N., Olopade, O. I., Weber, B. L., McLennan, J., Olivotto, I. A., Begin, L. R., & Narod, S. A. (2004). Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 10, 2029–2034.CrossRef
71.
Hosey, A. M., Gorski, J. J., Murray, M. M., Quinn, J. E., Chung, W. Y., Stewart, G. E., James, C. R., Farragher, S. M., Mulligan, J. M., Scott, A. N., Dervan, P. A., Johnston, P. G., Couch, F. J., Daly, P. A., Kay, E., McCann, A., Mullan, P. B., & Harkin, D. P. (2007). Molecular basis for estrogen receptor alpha deficiency in BRCA1-linked breast cancer. Journal of the National Cancer Institute, 99, 1683–1694.PubMedCrossRef
72.
Barone, I., Brusco, L., & Fuqua, S. A. (2010). Estrogen receptor mutations and changes in downstream gene expression and signaling. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 16, 2702–2708.CrossRef
73.
Cui, Y., Zhang, M., Pestell, R., Curran, E. M., Welshons, W. V., & Fuqua, S. A. (2004). Phosphorylation of estrogen receptor alpha blocks its acetylation and regulates estrogen sensitivity. Cancer Research, 64, 9199–9208.PubMedCrossRef
74.
Herynk, M. H., & Fuqua, S. A. (2004). Estrogen receptor mutations in human disease. Endocrine Reviews, 25, 869–898.PubMedCrossRef
75.
Ma, Y., Fan, S., Hu, C., Meng, Q., Fuqua, S. A., Pestell, R. G., Tomita, Y. A., & Rosen, E. M. (2010). BRCA1 regulates acetylation and ubiquitination of estrogen receptor-alpha. Molecular Endocrinology, 24, 76–90.PubMedCrossRef
76.
Kauff, N. D., Satagopan, J. M., Robson, M. E., Scheuer, L., Hensley, M., Hudis, C. A., Ellis, N. A., Boyd, J., Borgen, P. I., Barakat, R. R., Norton, L., Castiel, M., Nafa, K., & Offit, K. (2002). Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. The New England Journal of Medicine, 346, 1609–1615.PubMedCrossRef
77.
Bachelier, R., Li, C., Qiao, W., Furth, P. A., Lubet, R. A., & Deng, C. X. (2005). Effects of bilateral oophorectomy on mammary tumor formation in breast cancer associated gene 1 (Brca1) mutant mice. Oncology Reports, 14, 1117–1120.PubMed
78.
Ma, Y., Katiyar, P., Jones, L. P., Fan, S., Zhang, Y., Furth, P. A., & Rosen, E. M. (2006). The breast cancer susceptibility gene BRCA1 regulates progesterone receptor signaling in mammary epithelial cells. Molecular Endocrinology, 20, 14–34.PubMedCrossRef
79.
Poole, A. J., Li, Y., Kim, Y., Lin, S. C., Lee, W. H., & Lee, E. Y. (2006). Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist. Science, 314, 1467–1470.PubMedCrossRef
80.
Burga, L. N., Hu, H., Juvekar, A., Tung, N. M., Troyan, S. L., Hofstatter, E. W., & Wulf, G. M. (2011). Loss of BRCA1 leads to an increase in epidermal growth factor receptor expression in mammary epithelial cells, and epidermal growth factor receptor inhibition prevents estrogen receptor-negative cancers in BRCA1-mutant mice. Breast Cancer Research: BCR, 13, R30.PubMedCrossRef
81.
Rottenberg, S., Nygren, A. O., Pajic, M., van Leeuwen, F. W., van der Heijden, I., van de Wetering, K., Liu, X., de Visser, K. E., Gilhuijs, K. G., van Tellingen, O., Schouten, J. P., Jonkers, J., & Borst, P. (2007). Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 104, 12117–12122.PubMedCrossRef
82.
Shafee, N., Smith, C. R., Wei, S., Kim, Y., Mills, G. B., Hortobagyi, G. N., Stanbridge, E. J., & Lee, E. Y. (2008). Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors. Cancer Research, 68, 3243–3250.PubMedCrossRef
83.
Byrski, T., Huzarski, T., Dent, R., Gronwald, J., Zuziak, D., Cybulski, C., Kladny, J., Gorski, B., Lubinski, J., & Narod, S. A. (2009). Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Research and Treatment, 115, 359–363.PubMedCrossRef
84.
Bryant, H. E., & Helleday, T. (2004). Poly(ADP-ribose) polymerase inhibitors as potential chemotherapeutic agents. Biochemical Society Transactions, 32, 959–961.PubMedCrossRef
85.
Dantzer, F., Schreiber, V., Niedergang, C., Trucco, C., Flatter, E., De La Rubia, G., Oliver, J., Rolli, V., Menissier-de Murcia, J., & de Murcia, G. (1999). Involvement of poly(ADP-ribose) polymerase in base excision repair. Biochimie, 81, 69–75.PubMedCrossRef
86.
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005). Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature, 434, 913–917.PubMedCrossRef
87.
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., Martin, N. M., Jackson, S. P., Smith, G. C., & Ashworth, A. (2005). Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature, 434, 917–921.PubMedCrossRef
88.
De Soto, J. A., Wang, X., Tominaga, Y., Wang, R. H., Cao, L., Qiao, W., Li, C., Xu, X., Skoumbourdis, A. P., Prindiville, S. A., Thomas, C. J., & Deng, C. X. (2006). The inhibition and treatment of breast cancer with poly (ADP-ribose) polymerase (PARP-1) inhibitors. International Journal of Biological Sciences, 2, 179–185.PubMedCrossRef
89.
De Soto, J. A., & Deng, C. (2006). PARP-1 inhibitors, are they the long-sought genetically specific drugs for BRCA1/2-associated breast cancers? International Journal of Medical Sciences, 3, 117–123.PubMedCrossRef
90.
Rottenberg, S., Jaspers, J. E., Kersbergen, A., van der Burg, E., Nygren, A. O., Zander, S. A., Derksen, P. W., de Bruin, M., Zevenhoven, J., Lau, A., Boulter, R., Cranston, A., O’Connor, M. J., Martin, N. M., Borst, P., & Jonkers, J. (2008). High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proceedings of the National Academy of Sciences of the United States of America, 105, 17079–17084.PubMedCrossRef
91.
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O’Connor, M. J., Ashworth, A., Carmichael, J., Kaye, S. B., Schellens, J. H., & de Bono, J. S. (2009). Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. The New England Journal of Medicine, 361, 123–134.PubMedCrossRef
92.
Foulkes, W. D. (2004). BRCA1 functions as a breast stem cell regulator. Journal of Medical Genetics, 41, 1–5.PubMedCrossRef
93.
Somasundaram, V., & Srinivas, P. (2010). Insights into the targeted elimination of BRCA1-defective cancer stem cells. Medicinal Research Reviews, 32(5), 948–967.PubMedCrossRef
94.
Hakem, R., de la Pompa, J. L., Sirard, C., Mo, R., Woo, M., Hakem, A., Wakeham, A., Potter, J., Reitmair, A., Billia, F., Firpo, E., Hui, C. C., Roberts, J., Rossant, J., & Mak, T. W. (1996). The tumor suppressor gene Brca1 is required for embryonic cellular proliferation in the mouse. Cell, 85, 1009–1023.PubMedCrossRef
95.
Liu, C. Y., Flesken-Nikitin, A., Li, S., Zeng, Y., & Lee, W. H. (1996). Inactivation of the mouse Brca1 gene leads to failure in the morphogenesis of the egg cylinder in early postimplantation development. Genes & Development, 10, 1835–1843.CrossRef
96.
Gowen, L. C., Johnson, B. L., Latour, A. M., Sulik, K. K., & Koller, B. H. (1996). Brca1 deficiency results in early embryonic lethality characterized by neuroepithelial abnormalities. Nature Genetics, 12, 191–194.PubMedCrossRef
97.
Hohenstein, P., Kielman, M. F., Breukel, C., Bennett, L. M., Wiseman, R., Krimpenfort, P., Cornelisse, C., van Ommen, G. J., Devilee, P., & Fodde, R. (2001). A targeted mouse Brca1 mutation removing the last BRCT repeat results in apoptosis and embryonic lethality at the headfold stage. Oncogene, 20, 2544–2550.PubMedCrossRef
98.
Liu, X., Holstege, H., van der Gulden, H., Treur-Mulder, M., Zevenhoven, J., Velds, A., Kerkhoven, R. M., van Vliet, M. H., Wessels, L. F., Peterse, J. L., Berns, A., & Jonkers, J. (2007). Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 104, 12111–12116.PubMedCrossRef
99.
McCarthy, A., Savage, K., Gabriel, A., Naceur, C., Reis-Filho, J. S., & Ashworth, A. (2007). A mouse model of basal-like breast carcinoma with metaplastic elements. The Journal of Pathology, 211, 389–398.PubMedCrossRef
100.
Shakya, R., Szabolcs, M., McCarthy, E., Ospina, E., Basso, K., Nandula, S., Murty, V., Baer, R., & Ludwig, T. (2008). The basal-like mammary carcinomas induced by Brca1 or Bard1 inactivation implicate the BRCA1/BARD1 heterodimer in tumor suppression. Proceedings of the National Academy of Sciences of the United States of America, 105, 7040–7045.PubMedCrossRef
101.
Mak, T. W., Hakem, A., McPherson, J. P., Shehabeldin, A., Zablocki, E., Migon, E., Duncan, G. S., Bouchard, D., Wakeham, A., Cheung, A., Karaskova, J., Sarosi, I., Squire, J., Marth, J., & Hakem, R. (2000). Brcal required for T cell lineage development but not TCR loci rearrangement. Nature Immunology, 1, 77–82.PubMedCrossRef
102.
Berton, T. R., Matsumoto, T., Page, A., Conti, C. J., Deng, C. X., Jorcano, J. L., & Johnson, D. G. (2003). Tumor formation in mice with conditional inactivation of Brca1 in epithelial tissues. Oncogene, 22, 5415–5426.PubMedCrossRef
103.
Chodankar, R., Kwang, S., Sangiorgi, F., Hong, H., Yen, H. Y., Deng, C., Pike, M. C., Shuler, C. F., Maxson, R., & Dubeau, L. (2005). Cell-nonautonomous induction of ovarian and uterine serous cystadenomas in mice lacking a functional Brca1 in ovarian granulosa cells. Current Biology, 15, 561–565.PubMedCrossRef
104.
Quinn, B. A., Brake, T., Hua, X., Baxter-Jones, K., Litwin, S., Ellenson, L. H., & Connolly, D. C. (2009). Induction of ovarian leiomyosarcomas in mice by conditional inactivation of Brca1 and p53. PLoS One, 4, e8404.PubMedCrossRef
105.
Shakya, R., Reid, L. J., Reczek, C. R., Cole, F., Egli, D., Lin, C. S., deRooij, D. G., Hirsch, S., Ravi, K., Hicks, J. B., Szabolcs, M., Jasin, M., Baer, R., & Ludwig, T. (2011). BRCA1 tumor suppression depends on BRCT phosphoprotein binding, but not its E3 ligase activity. Science, 334, 525–528.PubMedCrossRef
106.
Pulvers, J. N., & Huttner, W. B. (2009). Brca1 is required for embryonic development of the mouse cerebral cortex to normal size by preventing apoptosis of early neural progenitors. Development, 136, 1859–1868.PubMedCrossRef
107.
Teoh, H., Quan, A., Creighton, A. K., Annie Bang, K. W., Singh, K. K., Shukla, P. C., Gupta, N., Pan, Y., Lovren, F., Leong-Poi, H., Al-Omran, M., & Verma, S. (2012). BRCA1 gene therapy reduces systemic inflammatory response and multiple organ failure and improves survival in experimental sepsis. Gene Therapy. doi:10.​1038/​gt.​2011.​214.
108.
Yang, Y., Swaminathan, S., Martin, B. K., & Sharan, S. K. (2003). Aberrant splicing induced by missense mutations in BRCA1: clues from a humanized mouse model. Human Molecular Genetics, 12, 2121–2131.PubMedCrossRef
109.
Drost, R., Bouwman, P., Rottenberg, S., Boon, U., Schut, E., Klarenbeek, S., Klijn, C., van der Heijden, I., van der Gulden, H., Wientjens, E., Pieterse, M., Catteau, A., Green, P., Solomon, E., Morris, J. R., & Jonkers, J. (2011). BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance. Cancer Cell, 20, 797–809.PubMedCrossRef
110.
Kim, E. H., Deng, C., Sporn, M. B., Royce, D. B., Risingsong, R., Williams, C. R., & Liby, K. T. (2012). CDDO-methyl ester delays breast cancer development in BRCA1-mutated mice. Cancer Prevention Research (Philadelphia, Pa.), 5, 89–97.CrossRef
111.
Kim, E. H., Deng, C. X., Sporn, M. B., & Liby, K. T. (2011). CDDO-imidazolide induces DNA damage, G2/M arrest and apoptosis in BRCA1-mutated breast cancer cells. Cancer Prevention Research (Philadelphia, Pa.), 4, 425–434.CrossRef
112.
Tominaga, Y., Wang, A., Wang, R. H., Wang, X., Cao, L., & Deng, C. X. (2007). Genistein inhibits Brca1 mutant tumor growth through activation of DNA damage checkpoints, cell cycle arrest, and mitotic catastrophe. Cell Death and Differentiation, 14, 472–479.PubMedCrossRef
113.
Wang, R. H., Zheng, Y., Kim, H. S., Xu, X., Cao, L., Luhasen, T., Lee, M. H., Xiao, C., Vassilopoulos, A., Chen, W., Gardner, K., Man, Y. G., Hung, M. C., Finkel, T., & Deng, C. X. (2008). Interplay among BRCA1, SIRT1, and Survivin during BRCA1-associated tumorigenesis. Molecular Cell, 32, 11–20.PubMedCrossRef
114.
Zander, S. A., Kersbergen, A., van der Burg, E., de Water, N., van Tellingen, O., Gunnarsdottir, S., Jaspers, J. E., Pajic, M., Nygren, A. O., Jonkers, J., Borst, P., & Rottenberg, S. (2010). Sensitivity and acquired resistance of BRCA1; p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan. Cancer Research, 70, 1700–1710.PubMedCrossRef
Metadaten
Titel
Mouse models of BRCA1 and their application to breast cancer research
verfasst von
Jennifer Dine
Chu-Xia Deng
Publikationsdatum
01.06.2013
Verlag
Springer US
Erschienen in
Cancer and Metastasis Reviews / Ausgabe 1-2/2013
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-012-9403-7

Weitere Artikel der Ausgabe 1-2/2013

Cancer and Metastasis Reviews 1-2/2013 Zur Ausgabe

NON-THEMATIC REVIEW

Hide and seek: tell-tale signs of breast cancer lurking in the blood

OriginalPaper

Humanised xenograft models of bone metastasis revisited: novel insights into species-specific mechanisms of cancer cell osteotropism

OriginalPaper

Mouse models of lung squamous cell carcinomas

NON-THEMATIC REVIEW

The role of the tissue omega-6/omega-3 fatty acid ratio in regulating tumor angiogenesis

OriginalPaper

Modeling prostate cancer in mice: something old, something new, something premalignant, something metastatic

OriginalPaper

Challenges and advances in mouse modeling for human pancreatic tumorigenesis and metastasis

Neu im Fachgebiet Onkologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

13.05.2024 Pankreaskarzinom Nachrichten

Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise